少突胶质细胞瘤切除术:监测、流行病学和最终结果(SEER)分析
基于SEER数据库(1999-2010年)分析2378例WHO II级和1028例WHO III级少突胶质细胞瘤患者,多因素Cox分析显示仅活检与全切除的死亡风险相当(O2组HR 1.06,95%CI 0.73-1.53;O3组HR 1.18,95%CI 0.80-1.72),文献综述亦无证据支持全切除改善总生存。
要点
- 仅活检与全切除相比,WHO II级和III级少突胶质细胞瘤患者的死亡风险无显著差异。
- 该系统评价与文献综述提示全切除与少突胶质细胞瘤总生存改善无关。
- 该结果与间变性星形细胞瘤和胶质母细胞瘤中全切除与总生存相关的报道形成对比。
核心结论
- 基于SEER的分析和文献综述提示,全切除与少突胶质细胞瘤患者总生存改善无关。
- 作者认为这一差异可能反映少突胶质细胞瘤较星形细胞瘤对化疗更敏感。
研究设计与样本
- 利用SEER数据库(1999-2010年)识别2378例WHO II级少突胶质细胞瘤患者(O2组)和1028例WHO III级少突胶质细胞瘤患者(O3组)。
- 切除程度定义为全切除、次全切除、仅活检或未切除,采用Kaplan-Meier和多因素Cox回归生存分析评估切除程度与生存的关系。
- 全面检索已发表文献,识别出8篇文章,均无令人信服的证据表明全切除与少突胶质细胞瘤总生存改善相关。
主要发现
- Cox多因素分析显示,仅活检与全切除相比,O2组死亡风险HR 1.06(95%CI 0.73-1.53),O3组HR 1.18(95%CI 0.80-1.72)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE The available evidence suggests that the clinical benefits of extended resection are limited for chemosensitive tumors, such as primary CNS lymphoma. Oligodendroglioma is generally believed to be more sensitive to chemotherapy than astrocytoma of comparable grades. In this study the authors compare the survival benefit of gross-total resection (GTR) in patients with oligodendroglioma relative to patients with astrocytoma. METHODS Using the Surveillance, Epidemiology, and End Results (SEER) Program (1999-2010) database, the authors identified 2378 patients with WHO Grade II oligodendroglioma (O2 group) and 1028 patients with WHO Grade III oligodendroglioma (O3 group). Resection was defined as GTR, subtotal resection, biopsy only, or no resection. Kaplan-Meier and multivariate Cox regression survival analyses were used to assess survival with respect to extent of resection. RESULTS Cox multivariate analysis revealed that the hazard of dying from O2 and O3 was comparable between patients who underwent biopsy only and GTR (O2: hazard ratio [HR] 1.06, 95% confidence interval [CI] 0.73-1.53; O3: HR 1.18, 95% CI 0.80-1.72). A comprehensive search of the published literature identified 8 articles without compelling evidence that GTR is associated with improved overall survival in patients with oligodendroglioma. CONCLUSIONS This SEER-based analysis and review of the literature suggest that GTR is not associated with improved survival in patients with oligodendroglioma. This finding contrasts with the documented association between GTR and overall survival in anaplastic astrocytoma and glioblastoma. The authors suggest that this difference may reflect the sensitivity of oligodendroglioma to chemotherapy as compared with astrocytomas.
引用
- Alattar AA, Brandel MG, Hirshman BR, et al. Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. J Neurosurg. 2017. PMID: 28498059. doi:10.3171/2016.11.JNS161974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。